Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

ClinicalTrials.gov ID: NCT05760300

Public ClinicalTrials.gov record NCT05760300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.

Study identification

NCT ID
NCT05760300
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Gilead Sciences
Industry
Enrollment
41 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2023
Primary completion
Jul 17, 2024
Completion
Jul 22, 2024
Last update posted
Sep 17, 2025

2023 – 2024

United States locations

U.S. sites
9
U.S. states
3
U.S. cities
7
Facility City State ZIP Site status
Velocity Clinical Research, New Smyrna Beach Edgewater Florida 32132
Clinical Pharmacology of Miami, LLC Miami Florida 33014
Advanced Pharma CR, LLC Miami Florida 33147
Panax Clinical Research Miami Lakes Florida 33014
Floridian Clinical Research, LLC Miami Lakes Florida 33016
Global Clinical Professionals Research St. Petersburg Florida 33705
Genesis Clinical Research, LLC Tampa Florida 33603
Massachusetts General Hospital - Renal Associates Clinic Boston Massachusetts 02114
Nucleus Network Saint Paul Minnesota 55114

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05760300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 17, 2025 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05760300 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →